122 The Professional Counselor | Volume 12, Issue 2 Stahl, S. M. (2021). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press. Surana, A. R., Agrawal, S. P., Kumbhare, M. R., & Gaikwad, S. B. (2021). Current perspectives in herbal and conventional drug interactions based on clinical manifestations. Future Journal of Pharmaceutical Sciences, 7(1), 1–12. https://doi.org/10.1186/s43094-021-00256-w Tallarida, R. J. (2007). Interactions between drugs and occupied receptors. Pharmacology & Therapeutics, 113(1), 197–209. https://doi.org/10.1016/j.pharmthera.2006.08.002 Tran, T., & Kavuluru, R. (2020). Social media surveillance for perceived therapeutic effects of cannabidiol (CBD) products. International Journal of Drug Policy, 77, 1–7. https://doi.org/10.1016/j.drugpo.2020.102688 U.S. Census Bureau. (2020). Quick facts [Table]. https://www.census.gov/quickfacts/fact/table/US/PST045219 U.S. Food & Drug Administration. (2015). FDA 101: Dietary supplements. https://www.fda.gov/consumers/ consumer-updates/fda-101-dietary-supplements U.S. Food & Drug Administration. (2020a). FDA approves new indication for drug containing an active ingredient derived from cannabis to treat seizures in rare genetic disease. https://www.fda.gov/news-events/pressannouncements/fda-approves-new-indication-drug-containing-active-ingredient-derived-cannabis-treatseizures-rare U.S. Food & Drug Administration. (2020b). What you need to know (and what we’re working to find out) about products containing cannabis or cannabis-derived compounds, including CBD. https://www.fda.gov/consumers/ consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containingcannabis-or-cannabis Wang, C.-C., Kennedy, J., & Wu, C.-H. (2015). Alternative therapies as a substitute for costly prescription medications: Results from the 2011 National Health Interview Survey. Clinical Therapeutics, 37(5), 1022– 1030. https://doi.org/10.1016/j.clinthera.2015.01.014 Wolf, M. S., King, J., Jacobson, K., Di Francesco, L., Bailey, S. C., Mullen, R., McCarthy, D., Serper, M., Davis, T. C., & Parker, R. M. (2012). Risk of unintentional overdose with non-prescription acetaminophen products. Journal of General Internal Medicine, 27(12), 1587–1593. https://doi.org/10.1007/s11606-012-2096-3 Wong, M. K., Darvishzadeh, A., Maler, N. A., & Bota, R. G. (2016). Five supplements and multiple psychotic symptoms: A case report. The Primary Care Companion for CNS Disorders, 18(1). https://doi.org/10.4088/PCC.15br01856 Wu, C.-H., Wang, C.-C., & Kennedy, J. (2011). Changes in herb and dietary supplement use in the US adult population: A comparison of the 2002 and 2007 National Health Interview Surveys. Clinical Therapeutics, 33(11), 1749–1758. https://doi.org/10.1016/j.clinthera.2011.09.024 Zirak, N., Shafiee, M., Soltani, G., Mirzaei, M., & Sahebkar, A. (2019). Hypericum perforatum in the treatment of psychiatric and neurodegenerative disorders: Current evidence and potential mechanisms of action. Journal of Cellular Physiology, 234(6), 8496–8508. https://doi.org/10.1002/jcp.27781
RkJQdWJsaXNoZXIy NDU5MTM1